drugset
drugset / Trial / NCT05787613

A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients

NCT05787613 ↗

Phase 2 Active not recruiting 132 enrolled Shanghai Henlius Biotech
RandomizedParallel-groupTriple-blindTreatment

Summary

A Phase II Study to Evaluate the Efficacy, Safety and Tolerability of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab (Anti-PD-1 Humanized Monoclonal Antibody Injection) and Chemotherapy in Previously Untreated Advanced Non-small Cell Lung Cancer (NSCLC) Patients

Timeline

Start
2023-07-10
Primary completion
2026-02
Completion
2027-07

Drugs

EvaluationDrugModalityDoseRoute
Subject HLX26 Monoclonal antibody 600 mg Intravenous
Subject HLX26 Monoclonal antibody 800 mg Intravenous
Subject Serplulimab Monoclonal antibody 300 mg Intravenous
Background Carboplatin Small molecule 5 unknown Intravenous
Background Paclitaxel Small molecule 100 mg/m2 Intravenous
Background Paclitaxel Small molecule 175 mg/m2 Intravenous
Background Pemetrexed Small molecule 500 mg/m2 Intravenous

Indications

non-small cell lung carcinoma